Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Am J Nephrol. 2020;51(7):501-510. doi: 10.1159/000508576. Epub 2020 Jul 8.
Frailty, originally characterized in community-dwelling older adults, is increasingly being studied and implemented for adult patients with end-stage kidney disease (ESKD) of all ages (>18 years). Frailty prevalence and manifestation are unclear in younger adults (18-64 years) with ESKD; differences likely exist based on whether the patients are treated with hemodialysis (HD) or kidney transplantation (KT).
We leveraged 3 cohorts: 378 adults initiating HD (2008-2012), 4,304 adult KT candidates (2009-2019), and 1,396 KT recipients (2008-2019). The frailty phenotype was measured within 6 months of dialysis initiation, at KT evaluation, and KT admission. Prevalence of frailty and its components was estimated by age (≥65 vs. <65 years). A Wald test for interactions was used to test whether risk factors for frailty differed by age.
In all 3 cohorts, frailty prevalence was higher among older than younger adults (HD: 71.4 vs. 47.3%; candidates: 25.4 vs. 18.8%; recipients: 20.8 vs. 14.3%). In all cohorts, older patients were more likely to have slowness and weakness but less likely to report exhaustion. Among candidates, older age (odds ratio [OR] = 1.79, 95% CI: 1.47-2.17), non-Hispanic black race (OR = 1.30, 95% CI: 1.08-1.57), and dialysis type (HD vs. no dialysis: OR = 2.06, 95% CI: 1.61-2.64; peritoneal dialysis vs. no dialysis: OR = 1.78, 95% CI: 1.28-2.48) were associated with frailty prevalence, but sex and Hispanic ethnicity were not. These associations did not differ by age (pinteractions > 0.1). Similar results were observed for recipients and HD patients.
Although frailty prevalence increases with age, younger patients have a high burden. Clinicians caring for this vulnerable population should recognize that younger patients may experience frailty and screen all age groups.
衰弱最初在社区居住的老年人中进行了描述,现在越来越多地在所有年龄段(> 18 岁)的终末期肾病(ESKD)成人患者中进行研究和实施。在年轻的 ESKD 成人(18-64 岁)中,衰弱的流行率和表现尚不清楚;基于患者接受血液透析(HD)或肾移植(KT)治疗的不同,差异可能存在。
我们利用了 3 个队列:378 名开始接受 HD(2008-2012 年)的成年人,4304 名成年 KT 候选者(2009-2019 年)和 1396 名 KT 受者(2008-2019 年)。在透析开始后 6 个月内,在 KT 评估和 KT 入院时测量衰弱表型。根据年龄(≥65 岁与<65 岁)估计衰弱的发生率及其组成部分。使用 Wald 检验进行交互作用检验,以检验衰弱的危险因素是否因年龄而异。
在所有 3 个队列中,老年患者的衰弱发生率均高于年轻患者(HD:71.4%比 47.3%;候选者:25.4%比 18.8%;受者:20.8%比 14.3%)。在所有队列中,老年患者更有可能出现缓慢和虚弱,但不太可能报告疲倦。在候选者中,年龄较大(OR=1.79,95%CI:1.47-2.17),非西班牙裔黑人种族(OR=1.30,95%CI:1.08-1.57)和透析类型(HD 与无透析:OR=2.06,95%CI:1.61-2.64;腹膜透析与无透析:OR=1.78,95%CI:1.28-2.48)与衰弱的发生率相关,但性别和西班牙裔种族则没有。这些关联在年龄上没有差异(p 交互作用>0.1)。在受者和 HD 患者中也观察到了类似的结果。
尽管衰弱的发生率随年龄增长而增加,但年轻患者的负担仍然很高。照顾这一脆弱人群的临床医生应认识到,年轻患者可能会经历衰弱,并应筛查所有年龄段的患者。